SCHEMBL6330885

SCHEMBL6330885

COC(=O)c1[nH]c2c([N+](C)(C)C)cccc2c1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.40
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
PADI4 Q9UM07 1/20 0.40
NR4A2 P43354 4/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TSHR P16473 2/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
RECQL P46063 1/20 0.37
MCL1 Q07820 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
IDO1 P14902 1/20 0.37
PTPN1 P18031 1/20 0.37
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18919754 0.81 NR4A2 (0.52) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL3338049 0.73 MEN1 (0.58) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL6331518 0.70 KDM4E (0.47) GAAKDM4EALDH1A1HTTNPSR1
Iodide SCHEMBL6330884 0.70 GLA (0.46) GAAGLA
SCHEMBL6400977 0.70 KDM4E (0.41) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL5110285 0.65 KDM4E (0.54) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL20569373 0.65 PARP15 (0.41) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL27385781 0.65 GABRA1 (0.44) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL4165663 0.64 ALOX5 (0.47) GAAKDM4EALDH1A1HTTNPSR1
SCHEMBL18919709 0.64 ALDH1A1 (0.44) GAAKDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2005-02-10 US disclosed
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins THE SCRIPPS RESEARCH INSTITUTE (US) 2004-01-01 US disclosed
US-6548530-B1 Antitumor drugs incorporate the 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one (CBI) alkylation subunit; cytotoxic activity THE SCRIPPS RESEARCH INSTITUTE 2003-04-15 US disclosed
EP-0862553-A4 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS SCRIPPS RESEARCH INST (US) 1999-02-03 EP disclosed
EP-0862553-A1 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS The Scripps Research Institute (US) 1998-09-09 EP disclosed
WO-1997012862-A1 CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS THE SCRIPPS RESEARCH INSTITUTE (US) 1997-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002528-A1 CBI analogs of CC-1065 and the duocarmycins DBI, DCK, CCNI GAA 2484/4885KDM4E 721/4885ALDH1A1 3378/4885
US-20050032860-A1 CBI analogs of CC-1065 and the duocarmycins DBI, CCNI, DCK GAA 2287/4885KDM4E 479/4885ALDH1A1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.